
Linda Granowetter MD
Hospice and Palliative Medicine(Pediatric Hematology and Oncology), Pediatric Sarcoma Oncology, Pediatric Solid Tumor Oncology
Professor, Pediatrics, New York University School of Medicine
Join to View Full Profile
160 E 32nd StFl 3New York, NY 10016
Phone+1 212-263-9660
Fax+1 212-263-8410
Dr. Granowetter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Children's Hospital of PhiladelphiaFellowship, Pediatric Hematology/Oncology, 1981 - 1984
Tower Health/St. Christopher's Hospital for ChildrenResidency, Pediatrics, 1979 - 1981
Stony Brook University Health Sciences Center School of MedicineClass of 1978
State University of New YorkB.S., Biology, 1974
State University of New YorkB.A., Liberal Arts, 1972
Certifications & Licensure
NY State Medical License 1987 - 2028
PA State Medical License 1980 - 1988
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2017
- TOP DOCTOR Castle Connolly, 2014
Clinical Trials
- Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2006 Sep 25
- Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
- Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Publications & Presentations
PubMed
- 45 citationsA randomized trial of the effectiveness of the neutropenic diet versus food safety guidelines on infection rate in pediatric oncology patientsKaren Moody, Rebecca Baker, Ruth Santizo, Inan Olmez, Jeanie Marie Spies
Pediatric Blood & Cancer. 2018-01-01 - 38 citationsIdentification of Patients With Localized Ewing Sarcoma at Higher Risk for Local Failure: A Report From the Children's Oncology Group.Safia K. Ahmed, R. Lor Randall, Steven G. DuBois, William S. Harmsen, Mark Krailo
International Journal of Radiation Oncology, Biology, Physics. 2017-12-01 - 75 citationsComparison of clinical features and outcomes in patients with extraskeletal versus skeletal localized Ewing sarcoma: A report from the Children's Oncology Group.Thomas Cash, Elizabeth McIlvaine, Mark Krailo, Stephen L. Lessnick, Elizabeth R. Lawlor
Pediatric Blood & Cancer. 2016-10-01
Journal Articles
- Cisplatinum nephrotoxicity in oncology therapeutics: retrospective review of patients treated between 2005 and 2012Finkel, Morgan; Goldstein, Adam; Steinberg, Yael; Granowetter, Linda; Trachtman, Howard, Pediatric Nephrology, 1/1/2014
- Topical Yunnan Baiyao administration as an adjunctive therapy for bleeding complications in adolescents with advanced cancerLadas EJ, Karlik JB, Rooney D, Taromina K, Ndao DH, Granowetter L, Kelly KM, Support Care Cancer, 12/1/2012
- Multivisceral ExVivo Surgery for Tumors Involving Celiac and Superior Mesenteric ArteriesKato T, Lobritto SJ, Tzakis A, Raveh Y, Sandoval PR, Martinez M, Granowetter L, Armas A, Brown JrRS, Emond J, Am J Transplant, 5/1/2012
Books/Book Chapters
Abstracts/Posters
- Evaluation of local control strategies in patients with localized Ewing sarcoma of bone: A report from the Children’s Oncology Group.DuBois SG, Krailo MD, Gebhardt, MC et al, J Clin Oncol; ASCO Meeting, 6/1/2012
- Topical Yunnan Baiyao Administration as an Adjunctive Therapy for Bleeding Complications in Adolescents with Advanced Cancer.Karlik, JB, Ladas, ED, Rooney, D, Taromina, K, Granowetter, L, Kelly, KM, American Academy of Pediatrics National Conference and Exhibition, New Orleans, LA, 1/1/2012
- Feasibility of bevacizumab (NSC 704865, BB-IND# 7921) combined with vincristine, topotecan, and cyclophosphamide in patients with first recurrent Ewing sarcoma (EWS): ...Leavey P, Glade Bender JL, Mascarenhas L, et al, J Clin Oncol; ASCO, 6/1/2010
Professional Memberships
- Member
- Connective Tissue Oncology SocietyMember
- Children's Oncology GroupMember
- American Society of Pediatric Hematology OncologyMember
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









